N/A
N=330
Evaluation of Point-of-Care (EPOC) for COVID-19
COVID-19 · SARS CoV 2 Infection
Bottom Line
View on ClinicalTrials.gov: NCT05227404 ↗Enrolled (actual)
330
Serious AEs
—
Results posted
Dec 2024
Primary outcome: Primary: Test Results Comparison Between LumiraDx and GenScript — 0.097 Unitless
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- LumiraDX (Diagnostic_test); RightSign (Diagnostic_test); Case Control (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Minnesota
- Primary completion
- Sep 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Test Results Comparison Between LumiraDx and GenScript |
0.097 | — |
| PRIMARY Comparison of Results Obtained by RightSign and GenScript |
-0.038 | — |
| SECONDARY LumiraDx Valid Test Frequency |
263 | — |
| SECONDARY RightSign Valid Test Frequency |
327 | — |
Summary
EPOC is designed to examine the feasibility of conducting two point-of-care (POC) tests the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test for SARS-CoV-2 antibodies and compare the reproducibility of these tests to tests run at a central laboratory on specimens obtained from the same study participants at the same time.
Eligibility Criteria
Inclusion Criteria
- Age ≥ 18 years.
- Informed consent by the patient or the patient's legally authorized representative (LAR) for up to 4 fingersticks for POC testing and a blood draw for stored blood samples.
- SARS-CoV-2 infection, documented by a nucleic acid test (NAT) or equivalent testing within 3 days prior to consent OR documented by NAT or equivalent testing more than 3 days prior to consent AND progressive disease suggestive of ongoing SARS-CoV-2 infection per the responsible investigator. (For non-NAT tests, only those deemed with equivalent specificity to NAT by the protocol team will be allowed. A central list of allowed non-NAT tests is maintained for TICO and that list will also be used for this protocol.)
- Duration of symptoms attributable to COVID-19 ≤ 12 days per the responsible investigator.
- Requiring admission for inpatient hospital acute medical care for clinical manifestations of COVID-19, per the responsible investigator, and NOT for purely public health or quarantine purposes.
Exclusion Criteria
- Prior receipt of SARS-CoV-2 hIVIG, convalescent plasma from a person who recovered from COVID-19, or SARS-CoV-2 nMAb within 6 months of the blood draws for testing as part of this protocol.
- Disease severity beyond that of stratum 1 in the TICO trial. This includes the following conditions:
- stroke
- meningitis
- encephalitis
- myelitis
- myocardial infarction
- myocarditis
- pericarditis
- symptomatic congestive heart failure (CHF; New York Heart Association [NYHA] class III-IV)
- arterial or deep venous thrombosis or pulmonary embolism
- Current requirement for any of the following:
- high-flow supplemental oxygen
- non-invasive ventilation
- invasive mechanical ventilation
- extracorporeal membrane oxygenation
- mechanical circulatory support
- vasopressor therapy
- commencement of renal replacement therapy at this admission (i.e., not patients on chronic renal replacement therapy).
- In the opinion of the responsible investigator, any condition for which, participation would not be in the best interest of the participant or that could limit protocol specified assessments.
Data sourced from ClinicalTrials.gov (NCT05227404). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.